Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma.

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linsitinib (Primary)
  • Indications Adrenocortical carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms GALACCTIC
  • Sponsors Astellas Pharma; OSI Pharmaceuticals

Most Recent Events

  • 30 May 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
  • 23 Oct 2012 Planned number of patients changed from 135 to 165 as reported by European Clinical Trials Database.
  • 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top